I just found this great SNNLive interview with Michael McFadden, CEO of Alpha Cognition ( $ACOG.V $ACOGF )
In the interview McFadden discusses the Alzhimer's drug, Biogen, that has been approved for use and how this affects $ACOG.
McFadden says that they are excited about the Biogen approval because it creates investor interest
Additionally he states that the approval of Biogen does not pose a threat of competition to the drugs $ACOG 's is developing because these drugs will likely compliment each other.
$ACOG 's drug helps with the cognitive effects of Alzheimer's which patients will likely still need help with even if they are taking Biogen.
Overall this is a great video to check out if you are invested in $ACOG or interested in the Alzhimer's pharmaceuticals sector in general,
$ACOG is trading for $1.33, MC $72.48M